## Kathleen M Aguilar

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3577199/publications.pdf

Version: 2024-02-01

1683934 1474057 9 116 5 9 citations g-index h-index papers 9 9 9 277 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Treatment patterns and clinical outcomes in patients with advanced non-small cell lung cancer initiating first-line treatment in the US community oncology setting: a real-world retrospective observational study. Journal of Cancer Research and Clinical Oncology, 2021, 147, 671-690.	1.2	30
2	An observational study of drug utilization and associated outcomes among adult patients diagnosed with BRAFâ€mutant advanced melanoma treated with firstâ€line antiâ€PDâ€l monotherapies or BRAF/MEK inhibitors in a communityâ€based oncology setting. Cancer Medicine, 2020, 9, 7863-7878.	1.3	4
3	Treatment Patterns and Healthcare Resource Utilization among Patients with Advanced or Metastatic Soft Tissue Sarcoma in US Community Practices. Sarcoma, 2020, 2020, 1-9.	0.7	2
4	<p>Treatment Sequencing Patterns in Patients with Metastatic Urothelial Cancer Treated in the Community Practice Setting in the United States: SPEAR-Bladder (Study informing treatment Pathway) Tj ETQq0 645-656.</p>	0 0 rgBT	/Oyerlock 10 <sup>-</sup>
5	Daratumumab Split First Versus Single Dosing Schedule Among Patients With Multiple Myeloma Treated in a US Community Oncology Setting: A Retrospective Observational Study. Clinical Therapeutics, 2019, 41, 866-881.e7.	1.1	9
6	A real-world comparative analysis of carfilzomib and other systemic multiple myeloma chemotherapies in a US community oncology setting. Therapeutic Advances in Hematology, 2019, 10, 204062071881669.	1.1	18
7	Real-world treatment patterns and clinical outcomes among patients with advanced melanoma. Medicine (United States), 2019, 98, e16328.	0.4	30
8	Ramucirumab for the treatment of patients with gastric or gastroesophageal junction cancer in community oncology practices. Gastric Cancer, 2018, 21, 831-844.	2.7	14
9	SPEAR-bladder (study informing treatment pathway decision in bladder cancer): First- through third-line time to treatment failure in the US Journal of Clinical Oncology, 2018, 36, 4544-4544.	0.8	4